C4 Therapeutics Inc.

7.07+0.5900+9.10%Vol 1.82M1Y Perf -82.62%
Jun 24th, 2022 16:00 DELAYED
BID6.88 ASK7.20
Open6.56 Previous Close6.48
Pre-Market- After-Market7.09
 - -  0.02 0.28%
Target Price
29.10 
Analyst Rating
Moderate Buy 1.67
Potential %
311.60 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     56.50
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★+     61.21
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.81 
Earnings Rating
Market Cap344.99M 
Earnings Date
10th Aug 2022
Alpha-0.07 Standard Deviation0.21
Beta2.80 

Today's Price Range

6.327.13

52W Range

4.8451.21

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
31.66%
1 Month
3.82%
3 Months
-71.54%
6 Months
-78.82%
1 Year
-82.62%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CCCC7.070.59009.10
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.61-0.65-6.56
Q04 2021-0.59-0.3147.46
Q03 2021-0.60-0.5115.00
Q02 2021-0.60-0.5115.00
Q01 2021-0.63-0.4922.22
Q03 2020-1.16-17.55-1 412.93
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date10th Aug 2022
Estimated EPS Next Report-0.68
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume1.82M
Shares Outstanding48.80K
Shares Float43.34M
Trades Count9.72K
Dollar Volume12.60M
Avg. Volume1.19M
Avg. Weekly Volume1.63M
Avg. Monthly Volume832.95K
Avg. Quarterly Volume1.10M

C4 Therapeutics Inc. (NASDAQ: CCCC) stock closed at 7.07 per share at the end of the most recent trading day (a 9.1% change compared to the prior day closing price) with a volume of 1.82M shares and market capitalization of 344.99M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 99 people. C4 Therapeutics Inc. CEO is Andrew Hirsch.

The one-year performance of C4 Therapeutics Inc. stock is -82.62%, while year-to-date (YTD) performance is -78.04%. CCCC stock has a five-year performance of %. Its 52-week range is between 4.84 and 51.21, which gives CCCC stock a 52-week price range ratio of 4.81%

C4 Therapeutics Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 0.72, a price-to-sale (PS) ratio of 5.69, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -21.26%, a ROC of -25.18% and a ROE of -30.10%. The company’s profit margin is -%, its EBITDA margin is -197.90%, and its revenue ttm is $46.01 Million , which makes it $0.94 revenue per share.

Of the last four earnings reports from C4 Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. C4 Therapeutics Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for C4 Therapeutics Inc. is Moderate Buy (1.67), with a target price of $29.1, which is +311.60% compared to the current price. The earnings rating for C4 Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

C4 Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

C4 Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.64, ATR14 : 0.66, CCI20 : 40.46, Chaikin Money Flow : 0.15, MACD : -0.59, Money Flow Index : 79.09, ROC : -5.23, RSI : 51.92, STOCH (14,3) : 74.83, STOCH RSI : 1.00, UO : 61.06, Williams %R : -25.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of C4 Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
6 (66.67 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (33.33 %)
3 (33.33 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.44

C4 Therapeutics Inc.

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

CEO: Andrew Hirsch

Telephone: +1 617 231-0700

Address: 490 Arsenal Way, Watertown 02472, MA, US

Number of employees: 99

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

52%48%

Bearish Bullish

54%46%

TipRanks News for CCCC

Fri, 08 Apr 2022 21:45 GMT C4 Therapeutics (CCCC) Gets a Buy Rating from Brookline Capital Markets

- TipRanks. All rights reserved.

News

Stocktwits